{"nctId":"NCT00782210","briefTitle":"12 / 48 Week Pivotal PFT vs PBO in COPD I","startDateStruct":{"date":"2008-11"},"conditions":["Pulmonary Disease, Chronic Obstructive"],"count":625,"armGroups":[{"label":"Olodaterol (BI 1744) Low","type":"EXPERIMENTAL","interventionNames":["Drug: Olodaterol (BI1744)"]},{"label":"Olodaterol (BI 1744) High","type":"EXPERIMENTAL","interventionNames":["Drug: Olodaterol (BI1744)"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: placebo"]}],"interventions":[{"name":"Olodaterol (BI1744)","otherNames":[]},{"name":"Olodaterol (BI1744)","otherNames":[]},{"name":"placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n* All patients must have a diagnosis of chronic obstructive pulmonary disease\n* Male or female patients, 40 years of age or older Patients must be current or ex-smokers with a smoking history of more than 10 pack years Post bronchodilator FEV1 \\<80% predicted and post-bronchodilator FEV1/FVC \\<70%\n\nExclusion criteria:\n\n* Patients with a significant disease other than COPD\n* Patients with a history of asthma\n* Patients with any of the following conditions:\n\na history of myocardial infarction within 1 year of screening visit (Visit 1) unstable or life-threatening cardiac arrhythmia. have been hospitalized for heart failure within the past year. known active tuberculosis a malignancy for which patient has undergone resection, radiation therapy or chemotherapy within last five years (patients with treated basal cell carcinoma are allowed) a history of life-threatening pulmonary obstruction a history of cystic fibrosis","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response at Day 85 (12 Weeks)","description":"Response was defined as change from baseline. Baseline FEV1 was defined as the mean of the -1 h and -10 min measurements performed just prior to administration of the first am dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit interaction as fixed categorical effects, baseline and baseline-by-visit interaction as fixed continuous covariates and patient as random effect. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.007","spread":"0.014"},{"groupId":"OG001","value":"0.165","spread":"0.014"},{"groupId":"OG002","value":"0.169","spread":"0.014"}]}]}]},{"type":"PRIMARY","title":"Trough FEV1 Response at Day 85 (12 Weeks)","description":"Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FEV1s if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.041","spread":"0.014"},{"groupId":"OG001","value":"0.050","spread":"0.014"},{"groupId":"OG002","value":"0.060","spread":"0.014"}]}]}]},{"type":"SECONDARY","title":"Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve 0-12 h (AUC 0-12h) Response at Day 85 (12 Weeks)","description":"Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. Means are adjusted using a non-mixed effects model with treatment (trt), tio stratum, baseline as fixed effects. FEV1 AUC 0-12h was calculated from 0-12 hours post-dose using the trapezoidal rule, divided by the observation time (12h) to report in litres.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.029","spread":"0.025"},{"groupId":"OG001","value":"0.144","spread":"0.022"},{"groupId":"OG002","value":"0.139","spread":"0.022"}]}]}]},{"type":"SECONDARY","title":"Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response at Day 1","description":"Response was defined as change from baseline. Baseline FEV1 was defined as the mean of the -1 h and -10 min measurements performed just prior to administration of the first dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit interaction as fixed categorical effects, baseline and baseline-by-visit interaction as fixed continuous covariates and patient as random effect. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.024","spread":"0.014"},{"groupId":"OG001","value":"0.189","spread":"0.014"},{"groupId":"OG002","value":"0.199","spread":"0.014"}]}]}]},{"type":"SECONDARY","title":"Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response After 2 Weeks","description":"Response was defined as change from baseline. Baseline FEV1 was defined as the mean of the -1 h and -10 min measurements performed just prior to administration of the first dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit interaction as fixed categorical effects, baseline and baseline-by-visit interaction as fixed continuous covariates and patient as random effect. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.000","spread":"0.014"},{"groupId":"OG001","value":"0.180","spread":"0.014"},{"groupId":"OG002","value":"0.192","spread":"0.014"}]}]}]},{"type":"SECONDARY","title":"Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response After 6 Weeks","description":"Response was defined as change from baseline. Baseline FEV1 was defined as the mean of the -1 h and -10 min measurements performed just prior to administration of the first dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit interaction as fixed categorical effects, baseline and baseline-by-visit interaction as fixed continuous covariates and patient as random effect. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.001","spread":"0.014"},{"groupId":"OG001","value":"0.169","spread":"0.014"},{"groupId":"OG002","value":"0.165","spread":"0.014"}]}]}]},{"type":"SECONDARY","title":"Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response After 24 Weeks","description":"Response was defined as change from baseline. Baseline FEV1 was defined as the mean of the -1 h and -10 min measurements performed just prior to administration of the first dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit interaction as fixed categorical effects, baseline and baseline-by-visit interaction as fixed continuous covariates and patient as random effect. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.18","spread":"0.014"},{"groupId":"OG001","value":"0.156","spread":"0.014"},{"groupId":"OG002","value":"0.143","spread":"0.014"}]}]}]},{"type":"SECONDARY","title":"Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response After 48 Weeks","description":"Response was defined as change from baseline. Baseline FEV1 was defined as the mean of the -1 h and -10 min measurements performed just prior to administration of the first dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit interaction as fixed categorical effects, baseline and baseline-by-visit interaction as fixed continuous covariates and patient as random effect. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.043","spread":"0.014"},{"groupId":"OG001","value":"0.130","spread":"0.014"},{"groupId":"OG002","value":"0.126","spread":"0.014"}]}]}]},{"type":"SECONDARY","title":"Trough FEV1 Response After 2 Weeks","description":"Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed a -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FEV1s if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.019","spread":"0.014"},{"groupId":"OG001","value":"0.076","spread":"0.014"},{"groupId":"OG002","value":"0.091","spread":"0.014"}]}]}]},{"type":"SECONDARY","title":"Trough FEV1 Response After 6 Weeks","description":"Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FEV1s if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.022","spread":"0.014"},{"groupId":"OG001","value":"0.073","spread":"0.014"},{"groupId":"OG002","value":"0.069","spread":"0.014"}]}]}]},{"type":"SECONDARY","title":"Trough FEV1 Response After 18 Weeks","description":"Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FEV1s if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.042","spread":"0.014"},{"groupId":"OG001","value":"0.056","spread":"0.014"},{"groupId":"OG002","value":"0.059","spread":"0.014"}]}]}]},{"type":"SECONDARY","title":"Trough FEV1 Response After 24 Weeks","description":"Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FEV1s if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.050","spread":"0.014"},{"groupId":"OG001","value":"0.036","spread":"0.014"},{"groupId":"OG002","value":"0.039","spread":"0.014"}]}]}]},{"type":"SECONDARY","title":"Trough FEV1 Response After 32 Weeks","description":"Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FEV1s if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.051","spread":"0.014"},{"groupId":"OG001","value":"0.041","spread":"0.014"},{"groupId":"OG002","value":"0.034","spread":"0.014"}]}]}]},{"type":"SECONDARY","title":"Trough FEV1 Response After 40 Weeks","description":"Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FEV1s if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.061","spread":"0.014"},{"groupId":"OG001","value":"0.046","spread":"0.014"},{"groupId":"OG002","value":"0.044","spread":"0.014"}]}]}]},{"type":"SECONDARY","title":"Trough FEV1 Response After 48 Weeks","description":"Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FEV1s if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.74","spread":"0.014"},{"groupId":"OG001","value":"0.019","spread":"0.014"},{"groupId":"OG002","value":"0.017","spread":"0.014"}]}]}]},{"type":"SECONDARY","title":"Peak FEV1 (0-3h) Response At Day 1","description":"Response was defined as change from baseline. Baseline peak FEV1 was defined as the mean of the available pre-dose peak FEV1 values prior to first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment.\n\nMeans are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by- visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.104","spread":"0.015"},{"groupId":"OG001","value":"0.259","spread":"0.015"},{"groupId":"OG002","value":"0.275","spread":"0.015"}]}]}]},{"type":"SECONDARY","title":"Peak FEV1 (0-3h) Response After 2 Weeks","description":"Response was defined as change from baseline. Baseline peak FEV1 was defined as the mean of the available pre-dose peak FEV1 values prior to first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.077","spread":"0.015"},{"groupId":"OG001","value":"0.254","spread":"0.015"},{"groupId":"OG002","value":"0.267","spread":"0.015"}]}]}]},{"type":"SECONDARY","title":"Peak FEV1 (0-3h) Response After 6 Weeks","description":"Response was defined as change from baseline. Baseline peak FEV1 was defined as the mean of the available pre-dose peak FEV1 values prior to first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.066","spread":"0.015"},{"groupId":"OG001","value":"0.238","spread":"0.015"},{"groupId":"OG002","value":"0.238","spread":"0.015"}]}]}]},{"type":"SECONDARY","title":"Peak FEV1 (0-3h) Response After 12 Weeks","description":"Response was defined as change from baseline. Baseline peak FEV1 was defined as the mean of the available pre-dose peak FEV1 values prior to first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.071","spread":"0.015"},{"groupId":"OG001","value":"0.235","spread":"0.015"},{"groupId":"OG002","value":"0.236","spread":"0.015"}]}]}]},{"type":"SECONDARY","title":"Peak FEV1 (0-3h) Response After 24 Weeks","description":"Response was defined as change from baseline. Baseline peak FEV1 was defined as the mean of the available pre-dose peak FEV1 values prior to first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.055","spread":"0.016"},{"groupId":"OG001","value":"0.230","spread":"0.015"},{"groupId":"OG002","value":"0.206","spread":"0.015"}]}]}]},{"type":"SECONDARY","title":"Peak FEV1 (0-3h) Response After 48 Weeks","description":"Response was defined as change from baseline. Baseline peak FEV1 was defined as the mean of the available pre-dose peak FEV1 values prior to first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.029","spread":"0.016"},{"groupId":"OG001","value":"0.198","spread":"0.016"},{"groupId":"OG002","value":"0.192","spread":"0.016"}]}]}]},{"type":"SECONDARY","title":"Forced Vital Capacity (FVC) Area Under Curve 0-3 Hours (AUC 0-3h) Response At Day 1","description":"Response was defined as change from baseline. Baseline FVC was defined as the mean of the available pre-dose FVC values prior to the first dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect. FVC AUC 0-3h was calculated using the trapezoidal rule, divided by the observation time to report in litres.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.063","spread":"0.027"},{"groupId":"OG001","value":"0.350","spread":"0.027"},{"groupId":"OG002","value":"0.392","spread":"0.027"}]}]}]},{"type":"SECONDARY","title":"Forced Vital Capacity (FVC) Area Under Curve 0-3 Hours (AUC 0-3h) Response After 2 Weeks","description":"Response was defined as change from baseline. Baseline FVC was defined as the mean of the available pre-dose FVC values prior to the first dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect. FVC AUC 0-3h was calculated using the trapezoidal rule, divided by the observation time to report in litres.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.026","spread":"0.027"},{"groupId":"OG001","value":"0.323","spread":"0.027"},{"groupId":"OG002","value":"0.353","spread":"0.027"}]}]}]},{"type":"SECONDARY","title":"FVC Area Under Curve 0-3 Hours (AUC 0-3h) Response After 6 Weeks","description":"Response was defined as change from baseline. Baseline FVC was defined as the mean of the available pre-dose FVC values prior to the first dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect. FVC AUC 0-3h was calculated using the trapezoidal rule, divided by the observation time to report in litres.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.022","spread":"0.028"},{"groupId":"OG001","value":"0.276","spread":"0.028"},{"groupId":"OG002","value":"0.316","spread":"0.027"}]}]}]},{"type":"SECONDARY","title":"FVC Area Under Curve 0-3 Hours (AUC 0-3h) Response After 12 Weeks","description":"Response was defined as change from baseline. Baseline FVC was defined as the mean of the available pre-dose FVC values prior to the first dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect. FVC AUC 0-3h was calculated using the trapezoidal rule, divided by the observation time to report in litres.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.003","spread":"0.028"},{"groupId":"OG001","value":"0.277","spread":"0.028"},{"groupId":"OG002","value":"0.295","spread":"0.028"}]}]}]},{"type":"SECONDARY","title":"FVC Area Under Curve 0-3 Hours (AUC 0-3h) Response After 24 Weeks","description":"Response was defined as change from baseline. Baseline FVC was defined as the mean of the available pre-dose FVC values prior to the first dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect. FVC AUC 0-3h was calculated using the trapezoidal rule, divided by the observation time to report in litres.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.026","spread":"0.028"},{"groupId":"OG001","value":"0.261","spread":"0.028"},{"groupId":"OG002","value":"0.281","spread":"0.028"}]}]}]},{"type":"SECONDARY","title":"FVC Area Under Curve 0-3 Hours (AUC 0-3h) Response After 48 Weeks","description":"Response was defined as change from baseline. Baseline FVC was defined as the mean of the available pre-dose FVC values prior to the first dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect. FVC AUC 0-3h was calculated using the trapezoidal rule, divided by the observation time to report in litres.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.040","spread":"0.028"},{"groupId":"OG001","value":"0.204","spread":"0.028"},{"groupId":"OG002","value":"0.231","spread":"0.028"}]}]}]},{"type":"SECONDARY","title":"Trough FVC Response After 2 Weeks","description":"Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVCs obtained at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FVCs if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.015","spread":"0.027"},{"groupId":"OG001","value":"0.132","spread":"0.027"},{"groupId":"OG002","value":"0.169","spread":"0.027"}]}]}]},{"type":"SECONDARY","title":"Trough FVC Response After 6 Weeks","description":"Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVCs obtained at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FVCs if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.005","spread":"0.027"},{"groupId":"OG001","value":"0.125","spread":"0.027"},{"groupId":"OG002","value":"0.135","spread":"0.027"}]}]}]},{"type":"SECONDARY","title":"Trough FVC Response After 12 Weeks","description":"Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVCs obtained at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FVCs if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.030","spread":"0.027"},{"groupId":"OG001","value":"0.085","spread":"0.027"},{"groupId":"OG002","value":"0.130","spread":"0.027"}]}]}]},{"type":"SECONDARY","title":"Trough FVC Response After 18 Weeks","description":"Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVCs obtained at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FVCs if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.028","spread":"0.028"},{"groupId":"OG001","value":"0.102","spread":"0.027"},{"groupId":"OG002","value":"0.134","spread":"0.027"}]}]}]},{"type":"SECONDARY","title":"Trough FVC Response After 24 Weeks","description":"Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVCs obtained at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FVCs if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.028","spread":"0.028"},{"groupId":"OG001","value":"0.055","spread":"0.027"},{"groupId":"OG002","value":"0.096","spread":"0.027"}]}]}]},{"type":"SECONDARY","title":"Trough FVC Response After 32 Weeks","description":"Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVCs obtained at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FVCs if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.026","spread":"0.028"},{"groupId":"OG001","value":"0.065","spread":"0.028"},{"groupId":"OG002","value":"0.097","spread":"0.027"}]}]}]},{"type":"SECONDARY","title":"Trough FVC Response After 40 Weeks","description":"Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVCs obtained at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FVCs if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.044","spread":"0.028"},{"groupId":"OG001","value":"0.087","spread":"0.028"},{"groupId":"OG002","value":"0.111","spread":"0.028"}]}]}]},{"type":"SECONDARY","title":"Trough FVC Response After 48 Weeks","description":"Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVCs obtained at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FVCs if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.083","spread":"0.028"},{"groupId":"OG001","value":"0.011","spread":"0.028"},{"groupId":"OG002","value":"0.032","spread":"0.028"}]}]}]},{"type":"SECONDARY","title":"FVC Peak (0-3h) Response At Day 1","description":"Response was defined as change from baseline. Baseline FVC peak (0-3h) was defined as the mean of the available pre-dose FVC peak (0-3h) values prior to first dose of randomized treatment. FVC Peak (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.245","spread":"0.029"},{"groupId":"OG001","value":"0.509","spread":"0.029"},{"groupId":"OG002","value":"0.546","spread":"0.029"}]}]}]},{"type":"SECONDARY","title":"FVC Peak (0-3h) Response After 2 Weeks","description":"Response was defined as change from baseline. Baseline FVC peak (0-3h) was defined as the mean of the available pre-dose FVC peak (0-3h) values prior to first dose of randomized treatment. FVC Peak (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.207","spread":"0.029"},{"groupId":"OG001","value":"0.471","spread":"0.029"},{"groupId":"OG002","value":"0.499","spread":"0.029"}]}]}]},{"type":"SECONDARY","title":"FVC Peak (0-3h) Response After 6 Weeks","description":"Response was defined as change from baseline. Baseline FVC peak (0-3h) was defined as the mean of the available pre-dose FVC peak (0-3h) values prior to first dose of randomized treatment. FVC Peak (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.180","spread":"0.029"},{"groupId":"OG001","value":"0.430","spread":"0.029"},{"groupId":"OG002","value":"0.460","spread":"0.029"}]}]}]},{"type":"SECONDARY","title":"FVC Peak (0-3h) Response After 12 Weeks","description":"Response was defined as change from baseline. Baseline FVC peak (0-3h) was defined as the mean of the available pre-dose FVC peak (0-3h) values prior to first dose of randomized treatment. FVC Peak (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.169","spread":"0.029"},{"groupId":"OG001","value":"0.421","spread":"0.029"},{"groupId":"OG002","value":"0.430","spread":"0.029"}]}]}]},{"type":"SECONDARY","title":"FVC Peak (0-3h) Response After 24 Weeks","description":"Response was defined as change from baseline. Baseline FVC peak (0-3h) was defined as the mean of the available pre-dose FVC peak (0-3h) values prior to first dose of randomized treatment. FVC Peak (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.188","spread":"0.030"},{"groupId":"OG001","value":"0.419","spread":"0.029"},{"groupId":"OG002","value":"0.420","spread":"0.030"}]}]}]},{"type":"SECONDARY","title":"FVC Peak (0-3h) Response After 48 Weeks","description":"Response was defined as change from baseline. Baseline FVC peak (0-3h) was defined as the mean of the available pre-dose FVC peak (0-3h) values prior to first dose of randomized treatment. FVC Peak (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.109","spread":"0.030"},{"groupId":"OG001","value":"0.356","spread":"0.030"},{"groupId":"OG002","value":"0.369","spread":"0.030"}]}]}]},{"type":"SECONDARY","title":"Forced Vital Capacity (FVC) Area Under Curve 0-12 h (AUC 0-12h) Response at Day 85 (12 Weeks)","description":"Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values prior to the first dose of randomized treatment. Means are adjusted using a non-mixed effects model with treatment (trt), tio stratum, baseline as fixed effects. FVC AUC 0-12h was calculated from 0-12 hours post-dose using the trapezoidal rule, divided by the observation time (12h) to report in litres.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.019","spread":"0.049"},{"groupId":"OG001","value":"0.283","spread":"0.045"},{"groupId":"OG002","value":"0.230","spread":"0.044"}]}]}]},{"type":"SECONDARY","title":"Weekly Mean Pre-dose Morning Peak Expiratory Flow Rate (PEF)","description":"Weekly mean pre-dose morning peak expiratory flow rate (PEF) at 48 weeks. PEFR measurements recorded by means of an e-Diary on a daily basis. This e-Diary was used to record the twice daily PEFs, study drug use, and rescue salbutamol (albuterol) use. The best of three readings for each measurement was recorded.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"180.019","spread":"3.182"},{"groupId":"OG001","value":"193.376","spread":"3.207"},{"groupId":"OG002","value":"195.475","spread":"3.184"}]}]}]},{"type":"SECONDARY","title":"Weekly Mean Evening Peak Expiratory Flow Rate (PEF)","description":"Weekly mean evening peak expiratory flow rate (PEF) at 48 weeks. PEFR measurements recorded by means of an e-Diary on a daily basis. This e-Diary was used to record the twice daily PEFs, study drug use, and rescue salbutamol (albuterol) use. The best of three readings for each measurement was recorded.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"190.676","spread":"3.165"},{"groupId":"OG001","value":"207.862","spread":"3.202"},{"groupId":"OG002","value":"205.236","spread":"3.166"}]}]}]},{"type":"SECONDARY","title":"Weekly Mean Daytime Rescue Use","description":"The patient was to record in the e-Diary the number of puffs of salbutamol (albuterol) Metered-Dose Inhaler used each day and night.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.487","spread":"0.136"},{"groupId":"OG001","value":"0.967","spread":"0.137"},{"groupId":"OG002","value":"0.839","spread":"0.136"}]}]}]},{"type":"SECONDARY","title":"Weekly Mean Nighttime Rescue Use","description":"The patient was to record in the e-Diary the number of puffs of salbutamol (albuterol) Metered-Dose Inhaler used each day and night.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.283","spread":"0.151"},{"groupId":"OG001","value":"1.701","spread":"0.152"},{"groupId":"OG002","value":"1.492","spread":"0.152"}]}]}]},{"type":"SECONDARY","title":"Weekly Mean Daily (24h) Rescue Use","description":"The patient was to record in the e-Diary the number of puffs of salbutamol (albuterol) Metered-Dose Inhaler used each day and night.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.747","spread":"0.265"},{"groupId":"OG001","value":"2.642","spread":"0.267"},{"groupId":"OG002","value":"2.312","spread":"0.265"}]}]}]},{"type":"SECONDARY","title":"Patient's Global Rating at Week 6","description":"Patients were asked to rate their respiratory condition relative to their condition prior to the first dose of study medication. The scale is a seven point scale: 1=very much better, 2=much better,3=a little better,4=no change,5=a little worse,6=much worse,7=very much worst.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","spread":"0.1"},{"groupId":"OG001","value":"3.0","spread":"0.1"},{"groupId":"OG002","value":"3.0","spread":"0.1"}]}]}]},{"type":"SECONDARY","title":"Patient's Global Rating at Week 12","description":"Patients were asked to rate their respiratory condition relative to their condition prior to the first dose of study medication. The scale is a seven point scale: 1=very much better, 2=much better,3=a little better,4=no change,5=a little worse,6=much worse,7=very much worst.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":"0.1"},{"groupId":"OG001","value":"3.0","spread":"0.1"},{"groupId":"OG002","value":"3.0","spread":"0.1"}]}]}]},{"type":"SECONDARY","title":"Patient's Global Rating at Week 24","description":"Patients were asked to rate their respiratory condition relative to their condition prior to the first dose of study medication. The scale is a seven point scale: 1=very much better, 2=much better,3=a little better,4=no change,5=a little worse,6=much worse,7=very much worst.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","spread":"0.1"},{"groupId":"OG001","value":"3.0","spread":"0.1"},{"groupId":"OG002","value":"3.0","spread":"0.1"}]}]}]},{"type":"SECONDARY","title":"Patient's Global Rating at Week 48","description":"Patients were asked to rate their respiratory condition relative to their condition prior to the first dose of study medication. The scale is a seven point scale: 1=very much better, 2=much better,3=a little better,4=no change,5=a little worse,6=much worse,7=very much worst.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":"0.1"},{"groupId":"OG001","value":"3.1","spread":"0.1"},{"groupId":"OG002","value":"3.1","spread":"0.1"}]}]}]},{"type":"SECONDARY","title":"Time to First Chronic Obstructive Pulmonary Disease (COPD) Exacerbation","description":"Qualifying events of COPD were specifically pre-defined in the protocol. Other respiratory related events were evaluated by the investigator to see if they met the pre-defined criteria. Time to event was measured from the beginning of treatment. Cox regression analysis of treatment effect using tiotropium stratum as a stratification factor. Due to the limited number of events some statistics were not able to be calculated and are listed as N/A or are blank. The measure type is the First Quartile.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"194.0","spread":null},{"groupId":"OG001","value":"160.0","spread":null},{"groupId":"OG002","value":"203.0","spread":null},{"groupId":"OG003","value":"236.0","spread":null},{"groupId":"OG004","value":"167.0","spread":null},{"groupId":"OG005","value":"239.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to First Chronic Obstructive Pulmonary Disease (COPD) Exacerbation Leading to Hospitalization","description":"Qualifying events of COPD were specifically pre-defined in the protocol. Other respiratory related events were evaluated by the investigator to see if they met the pre-defined criteria. These exacerbations required hospitalization. Time to event was measured from the beginning of treatment. Cox regression analysis of treatment effect using tiotropium stratum as a stratification factor. Due to the limited number of events some statistics were not able to be calculated and are listed as N/A or are blank. The measure type is the First Quartile.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null},{"groupId":"OG002","value":"NA","spread":null},{"groupId":"OG003","value":"NA","spread":null},{"groupId":"OG004","value":"NA","spread":null},{"groupId":"OG005","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to First Moderate Chronic Obstructive Pulmonary Disease (COPD) Exacerbation","description":"Qualifying events of COPD were specifically pre-defined in the protocol. Other respiratory related events were evaluated by the investigator to see if they met the pre-defined criteria. These exacerbations did not lead to hospitalization but included treatment with antibiotics and/or systemic steroids. Time to event was measured from the beginning of treatment. Cox regression analysis of treatment effect using tiotropium stratum as a stratification factor. Due to the limited number of events some statistics were not able to be calculated and are listed as N/A or are blank. The measure type is the First Quartile.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"194.0","spread":null},{"groupId":"OG001","value":"216.0","spread":null},{"groupId":"OG002","value":"218.0","spread":null},{"groupId":"OG003","value":"344.0","spread":null},{"groupId":"OG004","value":"170.0","spread":null},{"groupId":"OG005","value":"309.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of COPD Exacerbations","description":"Qualifying events of COPD were specifically pre-defined in the protocol. Other respiratory related events were evaluated by the investigator to see if they met the pre-defined criteria.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7476","spread":"0.0972"},{"groupId":"OG001","value":"0.5842","spread":"0.0791"},{"groupId":"OG002","value":"0.6322","spread":"0.0822"}]}]}]},{"type":"SECONDARY","title":"Number of COPD Exacerbations Requiring Hospitalization","description":"Qualifying events of COPD were specifically pre-defined in the protocol. Other respiratory related events were evaluated by the investigator to see if they met the pre-defined criteria. These exacerbations required hospitalization.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1010","spread":"0.0314"},{"groupId":"OG001","value":"0.0662","spread":"0.0224"},{"groupId":"OG002","value":"0.1133","spread":"0.0319"}]}]}]},{"type":"SECONDARY","title":"Number of Moderate Chronic Obstructive Pulmonary Disease (COPD) Exacerbations","description":"Qualifying events of COPD were specifically pre-defined in the protocol. Other respiratory related events were evaluated by the investigator to see if they met the pre-defined criteria. These exacerbations did not lead to hospitalization but included treatment with antibiotics and/or systemic steroids.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5745","spread":"0.0844"},{"groupId":"OG001","value":"0.4643","spread":"0.0714"},{"groupId":"OG002","value":"0.4875","spread":"0.0723"}]}]}]},{"type":"SECONDARY","title":"Changes in Safety Parameters Related to Treatment","description":"Occurrence of bronchoconstriction, cardiac disorders and investigations related to treatment. Bronchoconstriction is defined as any of the following events: Drop in trough FEV1 \\>= 15%, Rescue medication use within 30 min of inhaling randomized treatment on a clinic test day or Cough, wheeze, or dyspnoea AE within 30 min of inhaling randomized treatment on a clinic test day.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.4","spread":null},{"groupId":"OG001","value":"2.4","spread":null},{"groupId":"OG002","value":"3.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"1.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.5","spread":null},{"groupId":"OG002","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.5","spread":null},{"groupId":"OG002","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":null},{"groupId":"OG001","value":"0.5","spread":null},{"groupId":"OG002","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Potassium","description":"Laboratory testing: Average change from baseline of potassium measured. The laboratory tests at Day 1 were considered the baseline measurements.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.4"},{"groupId":"OG001","value":"0.0","spread":"0.3"},{"groupId":"OG002","value":"0.0","spread":"0.3"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":34,"n":209},"commonTop":["Chronic obstructive pulmonary disease","Upper respiratory tract infection","Nasopharyngitis","Cough","Bronchitis"]}}}